Surgical treatment of gastric, enteric and pancreatic endocrine tumors: Part 2. Treatment of hepatic metastases;Traitement chirurgical des tumeurs endocrines gastro-entéro- pancréatiques: 2. Traitement des métastases hépatiques

Journal de Chirurgie

Volumn 142, Issue 4, 2005, Pages 208-219

  Kianmanesh, R ^a,b   O'Toole, D ^a   Sauvanet, A ^a   Ruszniewski, P ^a   Belghiti, J ^a  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL LOUIS MOURIER   (France)

Author keywords

Endocrine tumor; Liver; Metastase; Treatment

Indexed keywords

EID: 24944454180     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0021-7697(05)80906-8     Document Type: Review

References (142)

1. Sutcliffe R, Maguire D, Ramage J et al. Management of neuroendocrine liver metastases. Am J Surg 2004;187:39-46.
2. Benevento A, Boni L, Frediani L et al. Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 2000;74:24-29.
3. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502-1522.
4. Que FG, Nagorney DM, Batts KP et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36-42.
5. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995;19:76-82.
6. Eriksson B, Skogseid B, Lundqvist G et al. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883-1890.
7. Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432-445.
8. Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 2001;81:511-525.
9. Elias D, Lasser P, Ducreux M et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003;133:375-382.
10. Sarmiento JM, Heywood G, Rubin J et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29-37.
11. Janson ET, Holmberg L, Stridsberg M et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-690.
12. Yu F, Venzon DJ, Serrano J et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999;17:615-630.
13. Weber HC, Venzon DJ, Lin JT et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995;108:1637-1649.
14. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol 1999;10 Suppl 4:170-176.
15. Jensen RT. Natural history of digestive endocrine tumors. In Mignon M, Colombel JF (eds): "Recent Advances in the pathology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;192-219.
16. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62 Suppl 1:51-58.
17. Droz JP, Flechon A, Lombard-Bohas C. [Chemotherapy of neuroendocrine tumors]. Rev Prat 2002;52:285-289.
18. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
19. Mitry E, Baudin E, Ducreux M et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355.
20. Mitry E, Rougier P. Treatement of poorly-differenciated neuroendocrine tumours. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;347-349.
21. O'Toole D, Kianmanesh R, Farges O, Ruszniewski P. [Treatment of pancreatic-duodenal endocrine tumors]. Rev Prat 2002;52:1546-1553.
22. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12:231-242.
23. Roche A, Girish BV, de Baere T et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003;13:136-140.
24. Partensky C. Prise en charge des tumeurs endocrines duodéno- pancréatiques. J Chir 2000;137:142-150.
25. Ducreux M, Ruszniewski P, Chayvialle JA et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-3281.
26. Di Bartolomeo M, Bajetta E, Buzzoni R et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-408.
27. Chanson P, Ducreux M. [Biotherapy of neuroendocrine tumors]. Rev Prat 2002;52:280-284.
28. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-693.
29. Droz JP, Flechon A, Lombard-Bohas C. [Chemotherapy of neuroendocrine tumors]. Rev Prat 2002;52:285-289.
30. Engstrom PF, Lavin PT, Moertel CG et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984;2:1255-1259.
31. Moertel CG, Johnson CM, McKusick MA et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-309.
32. Ruszniewski P. [Adjuvant treatment of endocrine digestive tumors]. Gastroenterol Clin Biol 1994;18:737-738.
33. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 2000;62 Suppl 1:79-83.
34. Roche A, Lasser P. [Locoregional therapy of neuroendocrine tumors]. Rev Prat 2002;52:274-278.
35. Carrasco CH, Charnsangavej C, Richli WJ, Wallace S. Intra-arterial cis-platinum in osteosarcoma. Haematol Blood Transfus 1987;31:52-56.
36. Ruszniewski P, Rougier P, Roche A et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71:2624-2630.
37. Dominguez S, Denys A, Menu Y, Ruszniewski P. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S213-S215.
38. Dominguez S, Denys A, Madeira I et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 2000;12:151-157.
39. Therasse E, Breittmayer F, Roche A et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993;189:541-547.
40. Wangberg B, Nilsson O, Johanson V, V et al. Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumor. Oncologist 1997;2:50-58.
41. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001;25:693-696.
42. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002;26:985-990.
43. Berber E, Herceg NL, Casto KJ, Siperstein AE. Laparoscopic radiofrequency ablation of hepatic tumors: prospective clinical evaluation of ablation size comparing two treatment algorithms. Surg Endosc 2004;18:390-396.
44. Bilchik AJ, Wood TF, Allegra D et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135:657-662.
45. Rose DM, Allegra DP, Bostick PJ et al. Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies. Am Surg 1999;65:1009-1014.
46. de Baere T, Elias D, Ducreux M et al. [Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]. Gastroenterol Clin Biol 1999;23:1128-1133.
47. Curley SA, Izzo F. Laparoscopic radiofrequency. Ann Surg Oncol 2000;7:78-79.
48. Bilchik AJ, Wood TF, Allegra D et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135:657-662.
49. de Baere T, Elias D, Dromain C et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000;175:1619-1625.
50. Elias D, Goharin A, El Otmany A et al. Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy. Eur J Surg Oncol 2000;26:763-769.
51. Curley SA, Marra P, Beaty K et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004;239:450-458.
52. Elias D, Baton O, Sideris L et al. Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 2004;11:500-505.
53. de Baere T, Elias D, Dromain C et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000;175:1619-1625.
54. Dromain C, de Baere T, Elias D et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 2002;223:255-262.
55. de Baere T, Roche A, Amenabar JM et al. Liver abscess formation after local treatment of liver tumors. Hepatology 1996;23:1436-1440.
56. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318.
57. Belghiti J, Hiramatsu K, Benoist S et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38-46.
58. Elias D, Cavalcanti A, Sabourin JC et al. Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol 1998;24:174-179.
59. Abdalla EK, Barnett CC, Doherty D et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675-680.
60. Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-825.
61. Curley SA, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev 2004;23:165-182.
62. Elias D, Cavalcanti dA, Eggenspieler P et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998;187:487-493.
63. Elias D, Lasser PH, Montrucolli D et al. Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol 1995;21:510-513.
64. Harrison LE, Brennan MF, Newman E et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 1997;121:625-632.
65. Vlastos G, Smith DL, Singletary SE et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 2004;11:869-874.
66. Benevento A, Boni L, Frediani L et al. Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol 2000;74:24-29.
67. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002;9:67-79.
68. Chen H, Hardacre JM, Uzar A et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88-92.
69. Madeira I, Terris B, Voss M et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998;43:422-427.
70. Chu QD, Hill HC, Douglass HO, Jr. et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002;9:855-862.
71. Baudin E, Dromain C. [Biology and imaging of neuroendocrine tumors]. Rev Prat 2002;52:268-273.
72. Dromain C, de Baere T, Baudin E et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003;180:121-128.
73. McEntee GP, Nagorney DM, Kvols LK et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091-1096.
74. Kianmanesh R, Farges O, Abdalla EK et al. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg 2003;197:164-170.
75. Dousset B, Saint-Marc O, Pitre J et al. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20:908-914.
76. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998;66:1307-1312.
77. Ringe B, Lorf T, Dopkens K, Canelo R. Treatment of hepatic metastases from gastroenteropancreatic neuroendocrine tumors: role of liver transplantation. World J Surg 2001;25:697-699.
78. Olausson M, Friman S, Cahlin C et al. Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg 2002;26:998-1004.
79. Ahlman H, Friman S, Cahlin C et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci 2004;1014:265-269.
80. Rosado B, Gores GJ. Liver transplantation for neuroendocrine tumors: progress and uncertainty. Liver Transpl 2004;10:712-713.
81. Florman S, Toure B, Kim L et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004;8:208-212.
82. Le Treut YP, Delpero JR, Dousset B et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997;225:355-364.
83. Park BJ, Alexander HR, Libutti SK et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery 1998;124:1056-1061.
84. Solorzano CC, Lee JE, Pisters PW et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-1085.
85. Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994;55 Suppl 3:98-103.
86. Vulierme MP. Tumeurs malignes. In Vilgrain V, Menu Y (eds): "Imagerie du foie, des voies biliaires, du pancréas et de la rate." Paris: Flammarion, 2002;43-71.
87. Henry-Feugeas MC, Debray MP, Schouman-Claeys E. MR imaging of digestive endocrine tumors. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;302-305.
88. Debray MP, Geoffroy O, Laissy JP et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001;74:1065-1070.
89. Voss M, Hammel P, Molas G et al. Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut 2000;46:244-249.
90. Ruszniewski P, Terris B. [Natural history and prognosis of pancreatic endocrine tumors]. Gastroenterol Clin Biol 2003;27:S20-S25.
91. Pelage JP, Soyer P, Boudiaf M et al. Carcinoid tumors of the abdomen: CT features. Abdom Imaging 1999;24:240-245.
92. Paulson EK, Fisher AJ, DeLong DM et al. Helical liver CT with computer-assisted bolus-tracking technology: is it possible to predict which patients will not achieve a threshold of enhancement? Radiology 1998;209:787-792.
93. Paulson EK, McDermott VG, Keogan MT et al. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998;206:143-150.
94. Vilgrain V. [Multidetector CT and MRI of malignant liver tumors]. J Radiol 2003;84:459-470.
95. Semelka RC, Cance WG, Marcos HB, Mauro MA. Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology 1999;213:86-91.
96. Inaba Y, Arai Y, Kanematsu M et al. Revealing hepatic metastases from colorectal cancer: value of combined helical CT during arterial portography and CT hepatic arteriography with a unified CT and angiography system. AJR Am J Roentgenol 2000;174:955-961.
97. van Erkel AR, Pijl ME, van den Berg-Huysmans AA et al. Hepatic metastases in patients with colorectal cancer: relationship between size of metastases, standard of reference, and detection rates. Radiology 2002;224:404-409.
98. Vogl TJ, Schwarz W, Blume S et al. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 2003;13:262-272.
99. Paulson EK, Fisher AJ, DeLong DM et al. Helical liver CT with computer-assisted bolus-tracking technology: is it possible to predict which patients will not achieve a threshold of enhancement? Radiology 1998;209:787-792.
100. Paulson EK, McDermott VG, Keogan MT et al. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 1998;206:143-150.
101. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995;19:76-82.
102. Yigitler C, Farges O, Kianmanesh R et al. The small remnant liver after major liver resection: how common and how relevant? Liver Transpl 2003;9:S18-S25.
103. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001;88:165-175.
104. Farges O, Denys A. [Portal vein embolization prior to hepatectomy. Techniques, indications and results]. Ann Chir 2001;126:836-844.
105. Farges O, Belghiti J, Kianmanesh R et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217.
106. Akerstrom G. Aspects on surgical strategy in midgut carcinoids and endocrine pancreatic tumors. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;330-334.
107. Ahlman H. Surgical treatment of neuroendocrine tumours with liver metastases. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." 1999;327-329.
108. Vauthey JN, Abdalla EK, Doherty DA et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002;8:233-240.
109. Sarmiento JM, Que FG, Grant CS et al. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 2002;132:976-982.
110. Norton JA, Warren RS, Kelly MG et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134:1057-1063.
111. Jaeck D, Oussoultzoglou E, Bachellier P et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001;25:689-692.
112. Shebani KO, Souba WW, Finkelstein DM et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229:815-821.
113. O'Grady JG, Polson RJ, Rolles K et al. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988;207:373-379.
114. Alsina AE, Bartus S, Hull D et al. Liver transplant for metastatic neuroendocrine tumor. J Clin Gastroenterol 1990;12:533-537.
115. Gores GJ. Liver transplantation for malignant disease. Gastroenterol Clin North Am 1993;22:285-299.
116. Schweizer RT, Alsina AE, Rosson R, Bartus SA. Liver transplantation for metastatic neuroendocrine tumors. Transplant Proc 1993;25:1973.
117. Frilling A, Rogiers X, Knofel WT, Broelsch CE. Liver transplantation for metastatic carcinoid tumors. Digestion 1994;55 Suppl 3:104-106.
118. Pichlmayr R, Weimann A, Oldhafer KJ et al. Role of liver transplantation in the treatment of unresectable liver cancer. World J Surg 1995;19:807-813.
119. Mignon M, Cadiot G, Marmuse JP, Lewin MJ. Is gastrinoma a medical disease? Yale J Biol Med 1996;69:289-300.
120. Martin M, Tarara D, Wu YM et al. Intrahepatic arterial chemoembolization for hepatocellular carcinoma and metastatic neuroendocrine tumors in the era of liver transplantation. Am Surg 1996;62:724-732.
121. Anthuber M, Jauch KW, Briegel J et al. Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 1996;20:73-76.
122. Pichlmayr R, Weimann A, Tusch G, Schlitt HJ. Indications and Role of Liver Transplantation for Malignant Tumors. Oncologist 1997;2:164-170.
123. Imam H, Eriksson B, Lukinius A et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997;36:607-614.
124. Lang H, Oldhafer KJ, Weimann A et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347-354.
125. Caplin ME, Hodgson HJ, Dhillon AP et al. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am J Gastroenterol 1998;93:1945-1948.
126. Miller CA, Ellison EC. Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am 1998;7:863-879.
127. Frilling A, Rogiers X, Malago M et al. Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg 1998;383:62-70.
128. Hengst K, Nashan B, Avenhaus W et al. Metastatic pancreatic VIPoma: deteriorating clinical course and successful treatment by liver transplantation. Z Gastroenterol 1998;36:239-245.
129. Bechstein WO, Pascher A, Neuhaus C. Liver transplantation in neuroendocrine tumors: which are the indications? In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;338-340.
130. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 2001;81:527-542.
131. el Rassi ZS, Ferdinand L, Mohsine RM et al. Primary and secondary liver endocrine tumors: clinical presentation, surgical approach and outcome. Hepatogastroenterology 2002;49:1340-1346.
132. Sutton R, Doran HE, Williams EM et al. Surgery for midgut carcinoid. Endocr Relat Cancer 2003;10:469-481.
133. Fernandez JA, Robles R, Marin C et al. Role of liver transplantation in the management of metastatic neuroendocrine tumors. Transplant Proc 2003;35:1832-1833.
134. Cahlin C, Friman S, Ahlman H et al. Liver transplantation for metastatic neuroendocrine tumor disease. Transplant Proc 2003;35:809-810.
135. Amarapurkar AD, Davies A, Ramage JK et al. Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. Eur J Gastroenterol Hepatol 2003;15:139-143.
136. Fenwick SW, Wyatt JI, Toogood GJ, Lodge JP. Hepatic resection and transplantation for primary carcinoid tumors of the liver. Ann Surg 2004;239:210-219.
137. Weinel RJ, Neuhaus C, Stapp J et al. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg 1993;218:640-645.
138. Farges O, Belghiti J. Options in the resection of endocrine tumours liver metastases. In Mignon M, Colombel JF (eds): "Recent advances in the pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors." Paris: 1999;335-337.
139. Frilling A, Malago M, Martin H, Broelsch CE. Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors. Surgery 1998;124:1000-1004.
140. Rosenau J, Bahr MJ, von Wasielewski R et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002;73:386-394.
141. Belghiti J, Durand F. Living donor liver transplantation: present and future. Br J Surg 2000;87:1441-1443.
142. Belghiti J, Revillon Y, Lacaille F, Durand F. [Liver transplantation with an intrafamilial living donor in the French context]. Gastroenterol Clin Biol 2001;25:110-111.